Wissenschaftl. Titel | LOGGIC/Firefly-2: A Phase 3, Randomized, International Multicenter Trial of DAY101 Monotherapy Versus Standard of Care Chemotherapy in Patients with Pediatric Low-Grade Glioma Harboring an Activating RAF Alteration Requiring First-Line Systemic Therapy |
Erkrankung |
Haema:
verschiedene Gliome:
Erstlinie
|
Molekularer Marker |
RAF |
Kurzprotokoll | Kurzprotokoll |
Links | Weiterführende Informationen (EudraCT) |
erstellt 18.10.2024 Data entry III CCP
geändert 18.10.2024 Data entry III CCP